General
Preferred name
atogepant
Synonyms
AGN241689 ()
MK8031. Atogepant ()
MK 8031 ()
AGN-241689 ()
MK-8031 ()
Qulipta ()
Aquipta ()
P&D ID
PD076531
CAS
1374248-81-3
Tags
available
drug
Approved by
FDA
First approval
2021
Drug indication
Migraine
migraine disorder
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Atogepant (MK-8031) is an orally active and selective calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine[1][2].
PRICE
394
DESCRIPTION
Atogepant is an oral calcitonin gene-related peptide receptor (CGRP) antagonist that was discovered by Merck, and which was developed as an anti-migraine therapeutic by Allergan/AbbVie .
(GtoPdb)
DESCRIPTION
Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
18
Molecular Weight
603.17
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
6
Aromatic Ring Count
3
cLogP
3.95
TPSA
104.29
Fraction CSP3
0.34
Chiral centers
4.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CGRP
CGRP Receptor
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data
